NURECANureca Limited
Healthcare · Medical Devices · NSE · as of 2026-10-26 (delayed ~30 min in market hours)
Nureca Limited provides home healthcare and wellness products in India. The company offers chronic disease products, such as nebulizers, blood pressure monitors, finger pulse oximeters, glucose meters, and thermometers, as well as connected products; orthopedic products, including massagers, pain management products, posture correctors, and rehabilitation products; and humidifiers and steamers, personal scales, yoga and exercise products, fitness tracking products, and dental and personal care products. It also provides mother and baby care products comprising baby feeding products, carry cots, baby skincare products, and bottle warmers and steamers; nutritional supplements and weight management products; and ECG products, fitness trackers, and smart weighing scales. In addition, the company provides orthopedic cushions, heating pads, and breast pumps. The company offers its products under the Dr Trust, Dr Physio, and Trumom brands. It markets its products through e-commerce platforms, distributors, retailers, and its websites. Nureca Limited was incorporated in 2016 and is based in Chandigarh, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
Why avoid
- • A bearish pattern is active and overall evidence is mixed
- • ROE: 2.5%
- • ROCE: 3.7%
- • RSI: 39
- • MACD: bearish
- • Double Top bearish signal (setup quality 61%)
Bull case
- • Revenue growth: 58.7% YoY
- • Profit growth: 35.3% YoY
- • Debt/Equity: 0.04
- • Price vs SMA200: above
Bear case
- • ROE: 2.5%
- • ROCE: 3.7%
- • RSI: 39
- • MACD: bearish
Key risks
- • Elevated volatility / drawdown profile — size positions accordingly
- • ROE: 2.5%
- • ROCE: 3.7%
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹15.63). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.